COVID-19 Impact on Global Immunotherapy Drugs for Multiple Myeloma Market Size, Status and Forecast 2020-2026

July 2020 | 99 pages | ID: C14B7F89E8AAEN
QYResearch

Abstracts

This report focuses on the global Immunotherapy Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Immunotherapy Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• Tonghua Dongbao Pharmaceutical
• Sumitomo
• Merck
• Biogen
• Schering-Plough
• Roche
• Glaxo
• Chiron

Market segment by Type, the product can be split into

• INF-?
• IL-6
• Rituximab
• Other

Market segment by Application, split into

• Hospital
• Drug Center
• Clinic
• Other

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Immunotherapy Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.
• To present the Immunotherapy Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Immunotherapy Drugs for Multiple Myeloma are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Immunotherapy Drugs for Multiple Myeloma Revenue
1.4 Market Analysis by Type
  1.4.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 INF-?
  1.4.3 IL-6
  1.4.4 Rituximab
  1.4.5 Other
1.5 Market by Application
  1.5.1 Global Immunotherapy Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
  1.5.2 Hospital
  1.5.3 Drug Center
  1.5.4 Clinic
  1.5.5 Other
1.6 Coronavirus Disease 2019 (Covid-19): Immunotherapy Drugs for Multiple Myeloma Industry Impact
  1.6.1 How the Covid-19 is Affecting the Immunotherapy Drugs for Multiple Myeloma Industry
    1.6.1.1 Immunotherapy Drugs for Multiple Myeloma Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Immunotherapy Drugs for Multiple Myeloma Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Immunotherapy Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Immunotherapy Drugs for Multiple Myeloma Market Perspective (2015-2026)
2.2 Immunotherapy Drugs for Multiple Myeloma Growth Trends by Regions
  2.2.1 Immunotherapy Drugs for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Immunotherapy Drugs for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  2.2.3 Immunotherapy Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Immunotherapy Drugs for Multiple Myeloma Market Growth Strategy
  2.3.6 Primary Interviews with Key Immunotherapy Drugs for Multiple Myeloma Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Immunotherapy Drugs for Multiple Myeloma Players by Market Size
  3.1.1 Global Top Immunotherapy Drugs for Multiple Myeloma Players by Revenue (2015-2020)
  3.1.2 Global Immunotherapy Drugs for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  3.1.3 Global Immunotherapy Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Immunotherapy Drugs for Multiple Myeloma Market Concentration Ratio
  3.2.1 Global Immunotherapy Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Immunotherapy Drugs for Multiple Myeloma Revenue in 2019
3.3 Immunotherapy Drugs for Multiple Myeloma Key Players Head office and Area Served
3.4 Key Players Immunotherapy Drugs for Multiple Myeloma Product Solution and Service
3.5 Date of Enter into Immunotherapy Drugs for Multiple Myeloma Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Immunotherapy Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)
4.2 Global Immunotherapy Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

5 IMMUNOTHERAPY DRUGS FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)
5.2 Global Immunotherapy Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
6.2 Immunotherapy Drugs for Multiple Myeloma Key Players in North America (2019-2020)
6.3 North America Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
6.4 North America Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
7.2 Immunotherapy Drugs for Multiple Myeloma Key Players in Europe (2019-2020)
7.3 Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
7.4 Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

8 CHINA

8.1 China Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
8.2 Immunotherapy Drugs for Multiple Myeloma Key Players in China (2019-2020)
8.3 China Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
8.4 China Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
9.2 Immunotherapy Drugs for Multiple Myeloma Key Players in Japan (2019-2020)
9.3 Japan Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
9.4 Japan Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
10.2 Immunotherapy Drugs for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
10.4 Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

11 INDIA

11.1 India Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
11.2 Immunotherapy Drugs for Multiple Myeloma Key Players in India (2019-2020)
11.3 India Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
11.4 India Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size (2015-2020)
12.2 Immunotherapy Drugs for Multiple Myeloma Key Players in Central & South America (2019-2020)
12.3 Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020)
12.4 Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 Tonghua Dongbao Pharmaceutical
  13.1.1 Tonghua Dongbao Pharmaceutical Company Details
  13.1.2 Tonghua Dongbao Pharmaceutical Business Overview and Its Total Revenue
  13.1.3 Tonghua Dongbao Pharmaceutical Immunotherapy Drugs for Multiple Myeloma Introduction
  13.1.4 Tonghua Dongbao Pharmaceutical Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020))
  13.1.5 Tonghua Dongbao Pharmaceutical Recent Development
13.2 Sumitomo
  13.2.1 Sumitomo Company Details
  13.2.2 Sumitomo Business Overview and Its Total Revenue
  13.2.3 Sumitomo Immunotherapy Drugs for Multiple Myeloma Introduction
  13.2.4 Sumitomo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.2.5 Sumitomo Recent Development
13.3 Merck
  13.3.1 Merck Company Details
  13.3.2 Merck Business Overview and Its Total Revenue
  13.3.3 Merck Immunotherapy Drugs for Multiple Myeloma Introduction
  13.3.4 Merck Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.3.5 Merck Recent Development
13.4 Biogen
  13.4.1 Biogen Company Details
  13.4.2 Biogen Business Overview and Its Total Revenue
  13.4.3 Biogen Immunotherapy Drugs for Multiple Myeloma Introduction
  13.4.4 Biogen Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.4.5 Biogen Recent Development
13.5 Schering-Plough
  13.5.1 Schering-Plough Company Details
  13.5.2 Schering-Plough Business Overview and Its Total Revenue
  13.5.3 Schering-Plough Immunotherapy Drugs for Multiple Myeloma Introduction
  13.5.4 Schering-Plough Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.5.5 Schering-Plough Recent Development
13.6 Roche
  13.6.1 Roche Company Details
  13.6.2 Roche Business Overview and Its Total Revenue
  13.6.3 Roche Immunotherapy Drugs for Multiple Myeloma Introduction
  13.6.4 Roche Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.6.5 Roche Recent Development
13.7 Glaxo
  13.7.1 Glaxo Company Details
  13.7.2 Glaxo Business Overview and Its Total Revenue
  13.7.3 Glaxo Immunotherapy Drugs for Multiple Myeloma Introduction
  13.7.4 Glaxo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.7.5 Glaxo Recent Development
13.8 Chiron
  13.8.1 Chiron Company Details
  13.8.2 Chiron Business Overview and Its Total Revenue
  13.8.3 Chiron Immunotherapy Drugs for Multiple Myeloma Introduction
  13.8.4 Chiron Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
  13.8.5 Chiron Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Immunotherapy Drugs for Multiple Myeloma Key Market Segments
Table 2. Key Players Covered: Ranking by Immunotherapy Drugs for Multiple Myeloma Revenue
Table 3. Ranking of Global Top Immunotherapy Drugs for Multiple Myeloma Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Immunotherapy Drugs for Multiple Myeloma Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of INF-?
Table 6. Key Players of IL-6
Table 7. Key Players of Rituximab
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Immunotherapy Drugs for Multiple Myeloma Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Immunotherapy Drugs for Multiple Myeloma Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Immunotherapy Drugs for Multiple Myeloma Players to Combat Covid-19 Impact
Table 14. Global Immunotherapy Drugs for Multiple Myeloma Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Regions (2015-2020)
Table 18. Global Immunotherapy Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Immunotherapy Drugs for Multiple Myeloma Market Growth Strategy
Table 24. Main Points Interviewed from Key Immunotherapy Drugs for Multiple Myeloma Players
Table 25. Global Immunotherapy Drugs for Multiple Myeloma Revenue by Players (2015-2020) (Million US$)
Table 26. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Players (2015-2020)
Table 27. Global Top Immunotherapy Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immunotherapy Drugs for Multiple Myeloma as of 2019)
Table 28. Global Immunotherapy Drugs for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Immunotherapy Drugs for Multiple Myeloma Product Solution and Service
Table 31. Date of Enter into Immunotherapy Drugs for Multiple Myeloma Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 34. Global Immunotherapy Drugs for Multiple Myeloma Market Size Share by Type (2015-2020)
Table 35. Global Immunotherapy Drugs for Multiple Myeloma Revenue Market Share by Type (2021-2026)
Table 36. Global Immunotherapy Drugs for Multiple Myeloma Market Size Share by Application (2015-2020)
Table 37. Global Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 38. Global Immunotherapy Drugs for Multiple Myeloma Market Size Share by Application (2021-2026)
Table 39. North America Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 41. North America Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 42. North America Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 43. North America Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 44. North America Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 45. Europe Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 47. Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 49. Europe Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 51. China Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 52. China Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 53. China Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 54. China Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 55. China Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 56. China Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 57. Japan Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 59. Japan Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 61. Japan Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 65. Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 67. Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 69. India Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 70. India Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 71. India Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 72. India Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 73. India Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 74. India Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Immunotherapy Drugs for Multiple Myeloma Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Immunotherapy Drugs for Multiple Myeloma Market Share (2019-2020)
Table 77. Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Immunotherapy Drugs for Multiple Myeloma Market Share by Type (2015-2020)
Table 79. Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Immunotherapy Drugs for Multiple Myeloma Market Share by Application (2015-2020)
Table 81. Tonghua Dongbao Pharmaceutical Company Details
Table 82. Tonghua Dongbao Pharmaceutical Business Overview
Table 83. Tonghua Dongbao Pharmaceutical Product
Table 84. Tonghua Dongbao Pharmaceutical Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 85. Tonghua Dongbao Pharmaceutical Recent Development
Table 86. Sumitomo  Company Details
Table 87. Sumitomo  Business Overview
Table 88. Sumitomo  Product
Table 89. Sumitomo  Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 90. Sumitomo  Recent Development
Table 91. Merck Company Details
Table 92. Merck Business Overview
Table 93. Merck Product
Table 94. Merck Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 95. Merck Recent Development
Table 96. Biogen Company Details
Table 97. Biogen Business Overview
Table 98. Biogen Product
Table 99. Biogen Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 100. Biogen Recent Development
Table 101. Schering-Plough Company Details
Table 102. Schering-Plough Business Overview
Table 103. Schering-Plough Product
Table 104. Schering-Plough Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 105. Schering-Plough Recent Development
Table 106. Roche Company Details
Table 107. Roche Business Overview
Table 108. Roche Product
Table 109. Roche Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 110. Roche Recent Development
Table 111. Glaxo Company Details
Table 112. Glaxo Business Overview
Table 113. Glaxo Product
Table 114. Glaxo Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 115. Glaxo Recent Development
Table 116. Chiron Business Overview
Table 117. Chiron Product
Table 118. Chiron Company Details
Table 119. Chiron Revenue in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020) (Million US$)
Table 120. Chiron Recent Development
Table 121. Research Programs/Design for This Report
Table 122. Key Data Information from Secondary Sources
Table 123. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Type: 2020 VS 2026
Figure 2. INF-? Features
Figure 3. IL-6 Features
Figure 4. Rituximab Features
Figure 5. Other Features
Figure 6. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
Figure 7. Hospital Case Studies
Figure 8. Drug Center Case Studies
Figure 9. Clinic Case Studies
Figure 10. Other Case Studies
Figure 11. Immunotherapy Drugs for Multiple Myeloma Report Years Considered
Figure 12. Global Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth 2015-2026 (US$ Million)
Figure 13. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Regions: 2020 VS 2026
Figure 14. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
Figure 15. Porter's Five Forces Analysis
Figure 16. Global Immunotherapy Drugs for Multiple Myeloma Market Share by Players in 2019
Figure 17. Global Top Immunotherapy Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immunotherapy Drugs for Multiple Myeloma as of 2019
Figure 18. The Top 10 and 5 Players Market Share by Immunotherapy Drugs for Multiple Myeloma Revenue in 2019
Figure 19. North America Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Europe Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. China Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Japan Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Southeast Asia Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. India Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Central & South America Immunotherapy Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Tonghua Dongbao Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Tonghua Dongbao Pharmaceutical Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 28. Sumitomo  Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Sumitomo  Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 30. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Merck Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 32. Biogen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Biogen Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 34. Schering-Plough Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Schering-Plough Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 36. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Roche Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 38. Glaxo Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. Glaxo Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 40. Chiron Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Chiron Revenue Growth Rate in Immunotherapy Drugs for Multiple Myeloma Business (2015-2020)
Figure 42. Bottom-up and Top-down Approaches for This Report
Figure 43. Data Triangulation
Figure 44. Key Executives Interviewed